TOM1L2

Across TCGA pan-cancer cohorts, TOM1L2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TOM1L2 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TOM1L2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TOM1L2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, GBM, and LUAD are the cancer types where TOM1L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.990	0.844	.001	86	view →
GBM	OS	Tertile	All	0.266	0.636	.015	5	view →
LUAD	DFS	Median	III,IV	0.305	0.690	.032	2	view →
PDAC	OS	Quartile	All	0.637	0.471	.041	1	view →
LSCC	DFS	Tertile	II,III,IV	0.890	1.000	.016	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TOM1L2–CCRCC (DFS)

Open the CCRCC breakdown →